ROG

Roche expands long-term alliance with Sysmex

Retrieved on: 
Thursday, August 3, 2023
ROG, RO, Partnership, Hematology, Patient, Laboratory, Sysmex Corporation, Fine chemical

Roche has been collaborating with Sysmex for 25 years and through the renewed terms, Roche will continue to offer Sysmex' hematology products, complementing their total lab solutions portfolio.

Key Points: 
  • Roche has been collaborating with Sysmex for 25 years and through the renewed terms, Roche will continue to offer Sysmex' hematology products, complementing their total lab solutions portfolio.
  • "We are delighted to expand our 25-year partnership with Sysmex in the area of hematology and in exploring more sustainable diagnostics solutions.
  • Roche and Sysmex both have a long-standing history of delivering reliable and innovative solutions for patients and I am very happy to see this collaboration grow," said Matt Sause, CEO of Roche Diagnostics.
  • "We are pleased to announce the renewal of our partnership with Roche, reaffirming our commitment to long-term collaboration.

Roche expands long-term alliance with Sysmex

Retrieved on: 
Thursday, August 3, 2023
ROG, RO, Partnership, Hematology, Patient, Laboratory, Sysmex Corporation, Fine chemical

Roche has been collaborating with Sysmex for 25 years and through the renewed terms, Roche will continue to offer Sysmex' hematology products, complementing their total lab solutions portfolio.

Key Points: 
  • Roche has been collaborating with Sysmex for 25 years and through the renewed terms, Roche will continue to offer Sysmex' hematology products, complementing their total lab solutions portfolio.
  • "We are delighted to expand our 25-year partnership with Sysmex in the area of hematology and in exploring more sustainable diagnostics solutions.
  • Roche and Sysmex both have a long-standing history of delivering reliable and innovative solutions for patients and I am very happy to see this collaboration grow," said Matt Sause, CEO of Roche Diagnostics.
  • "We are pleased to announce the renewal of our partnership with Roche, reaffirming our commitment to long-term collaboration.

Rogers Schedules Second Quarter 2023 Earnings Call for August 3

Retrieved on: 
Thursday, July 20, 2023
Engineering, Chemicals, Plastics, Automotive Manufacturing, Manufacturing, Other Manufacturing, Machinery, Rogers Corporation, ROG, Senior, NYSE, Management

Rogers Corporation (NYSE:ROG) (“Rogers”) plans to announce second quarter results on August 3 after market close, which will be followed by a conference call at 5:00 pm ET.

Key Points: 
  • Rogers Corporation (NYSE:ROG) (“Rogers”) plans to announce second quarter results on August 3 after market close, which will be followed by a conference call at 5:00 pm ET.
  • The call will be hosted by Colin Gouveia, President and Chief Executive Officer, who will be joined by Ram Mayampurath, Senior Vice President and Chief Financial Officer.
  • A live webcast of the event and related slide presentation can be accessed on Rogers’ Investors Relations website at https://rogerscorp.com/investors .
  • A replay of the event will also be available on the Investor Relations’ website.

New Clinical and Real-World Data for Genentech’s Vabysmo at ASRS Reveal Improved Outcomes for People With Two Leading Causes of Vision Loss

Retrieved on: 
Thursday, July 20, 2023
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Retina, Abstract, DME, ERM, AMD, Anatomy, Paratriathlon, Eye, Neovascularization, Diabetic retinopathy, ROG, RO, Wet, Patient, Data, Ophthalmology, Annual general meeting, United Kingdom, Society, Macular degeneration, ASRS, Update, Roche, Pharmaceutical industry, Medical imaging, Faricimab, Genentech

“The clinical and real-world data at ASRS reinforce the improvement in outcomes brought by Vabysmo in two leading causes of vision loss, particularly new analyses suggesting that Vabysmo is associated with less vision-impacting fibrosis than aflibercept,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development.

Key Points: 
  • “The clinical and real-world data at ASRS reinforce the improvement in outcomes brought by Vabysmo in two leading causes of vision loss, particularly new analyses suggesting that Vabysmo is associated with less vision-impacting fibrosis than aflibercept,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development.
  • Wet AMD and DME are two leading causes of vision loss, together affecting more than two million people in the United States and 40 million people globally.
  • Data will also further support how increased intervals between doses of Vabysmo to treat wet AMD and DME, compared to aflibercept, do not compromise outcomes.
  • Elevatum Study Design and Rationale: A Phase 4 Trial of Faricimab (VABYSMO) in Underrepresented Patients With Diabetic Macular Edema

Roche to showcase next-generation diagnostic solutions at the American Association of Clinical Chemistry 2023 Clinical Lab Expo

Retrieved on: 
Wednesday, July 19, 2023
RFP, Partnership, Mayo Clinic, Medical laboratory, University, AACC, Heart failure, STRONG, FACC, Personalized medicine, Pathology, Immunoassay, MSCS, Mass spectrometry, PST, Sale, Science, Maryland School, ROG, RO, University of Texas Southwestern Medical Center, CCM, FAHA, ISE, Internal medicine, Ion-selective electrode, University of Maryland School of Medicine, Cardiology, Health, Alzheimer's disease, Medicine, Fine chemical, Pharmaceutical industry, Communications satellite

The Roche exhibit booth and Roche Idea Lab series featuring industry experts will highlight how our commitments to science, operational simplicity and partnership can improve patient care.

Key Points: 
  • The Roche exhibit booth and Roche Idea Lab series featuring industry experts will highlight how our commitments to science, operational simplicity and partnership can improve patient care.
  • INDIANAPOLIS and ANAHEIM, Calif., July 19, 2023 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) will showcase a science-driven and patient-centric exhibit at the 2023 American Association of Clinical Chemistry (AACC) Scientific Meeting and Clinical Lab Expo, July 23-27 in Anaheim, California.
  • These systems can provide healthcare communities with the future benefit of an extended diagnostic platform offering clinical chemistry, molecular diagnostics, immunoassays and mass spectrometry.
  • For more information about Roche's participation at AACC 2023 and Roche Idea Lab programming, visit AACC.roche.com .

Air Products to Supply Hydrogen and Fueling Technology to Edmonton International Airport for Alberta's First Hydrogen Fuel Cell Passenger Vehicle Fleet

Retrieved on: 
Thursday, July 13, 2023
Hydrogen, Natural Resources Canada, CAD, Imperial, Carbon, Toyota, Government, Natural Resources, ROG, Air Products, Natural gas, Edmonton Airports, Mirai, Mobility, Transport, Edmonton International Airport, NYSE, Toyota Canada, Oil, Jet fuel, Province

LEHIGH VALLEY, Pa., July 13, 2023 /PRNewswire/ -- Air Products (NYSE: APD), the world's largest producer of hydrogen and a first-mover in energy transition projects, today announced that it has been selected by Edmonton International Airport as the hydrogen and technology provider for Alberta's first hydrogen fuel cell passenger vehicle fleet.

Key Points: 
  • Under the agreement, Air Products will station a mobile hydrogen refueler at the airport to provide hydrogen for the fleet of Toyota Mirai hydrogen fuel cell vehicles.
  • Myron Keehn, President and CEO of Edmonton Airports, including Edmonton International Airport, made the announcement today during a luncheon with Toyota Canada, where they unveiled plans to partner to create the Province's first hydrogen fuel cell passenger vehicle fleet.
  • "Air Products is proud to support Edmonton International Airport in this first-mover project to establish the first passenger hydrogen fuel cell vehicle fleet in Alberta," said Eric Guter , Air Products' Global Vice President, Hydrogen for Mobility.
  • Earlier this year, Air Products announced plans to build the first commercial-scale hydrogen refueling station in Edmonton.

Positive Phase III Results for Genentech’s Ocrevus (ocrelizumab) Twice a Year, 10-Minute Subcutaneous Injection in Patients With Multiple Sclerosis

Retrieved on: 
Thursday, July 13, 2023
Research, Entertainment, Genetics, Clinical Trials, General Entertainment, Biotechnology, Radiology, Pharmaceutical, Health, Science, IV, Disability, Roche, Pharmacokinetics, Brain, MS, ROG, RO, MRI, RMS, Magnetic resonance imaging, Patient, Blood, PPMS, Phase, Disease, Pharmaceutical industry, Genentech, Ocrelizumab

Ocrevus subcutaneous injection was shown to be non-inferior to Ocrevus given by intravenous infusion (IV), as measured by pharmacokinetics (levels in the blood) over 12 weeks.

Key Points: 
  • Ocrevus subcutaneous injection was shown to be non-inferior to Ocrevus given by intravenous infusion (IV), as measured by pharmacokinetics (levels in the blood) over 12 weeks.
  • Ocrevus subcutaneous injection was also comparable with Ocrevus IV in controlling magnetic resonance imaging (MRI) lesion activity in the brain over 12 weeks.
  • The safety profile of Ocrevus subcutaneous injection was consistent with that of Ocrevus IV.
  • The Ocrevus 10-minute injection is designed to be administered without the need for IV infrastructure so it has the potential to expand the usage of Ocrevus in MS centers without IV infrastructure or those with IV capacity limitations.

Rogers Releases 2023 Environmental, Social and Governance Report Supplement

Retrieved on: 
Friday, June 30, 2023
Environmental, Social and Governance (ESG), Automotive Manufacturing, Alternative Energy, Energy, Green Technology, Manufacturing, Consumer Electronics, Technology, EV, Electric Vehicles, Professional Services, Environment, Autonomous Driving, Vehicles, Automotive, Other Energy, Engineering, Social Security Government Pension Offset, Rogers Corporation, ROG, ESG, Social, Report, NYSE, Rogers, Culture, Cryptocurrency

Rogers Corporation (NYSE:ROG) (“Rogers”), announced today that it has issued an update (Report Supplement) to its 2021 Environmental, Social and Governance (ESG) Report.

Key Points: 
  • Rogers Corporation (NYSE:ROG) (“Rogers”), announced today that it has issued an update (Report Supplement) to its 2021 Environmental, Social and Governance (ESG) Report.
  • “For decades Rogers has been a leader in innovative materials solutions, which enable technologies that improve lives and help create a more sustainable world,” said Colin Gouveia, Rogers' President and CEO.
  • “Our commitment to corporate responsibility and sustainability is deeply embedded in our culture, and we strive to demonstrate this commitment in both the way we operate and by enabling sustainable end markets, such as electric vehicles and renewable energy.
  • Today’s report highlights the progress we are making, and we look forward to building on our accomplishments as we continue on our sustainability journey.”
    Covers the period from January 1, 2022 to December 31, 2022

Four-Year Follow-Up Data for Genentech’s Evrysdi Show Continued Increase in Number of Children With a Severe Form of Spinal ​Muscular ​Atrophy (SMA)​ Able to Sit, Stand and Walk

Retrieved on: 
Friday, June 30, 2023
Biotechnology, Consumer, Health, Pharmaceutical, Children, SMN, SMA, Disease, PTC Therapeutics, SMN2, PTC, Aes, Roche, Cure, Medicine, ROG, RO, Bayley Scales of Infant Development, Walking, Patient, Infant, Ageing, Upper respiratory tract infection, Therapy, Pneumonia, Mouth, UCL Great Ormond Street Institute of Child Health, Birth control, Pharmaceutical industry, Genentech, Fever, Risdiplam

After four years of treatment with Evrysdi, many of the babies, now young children, continued to improve their ability to sit, stand and walk without support.

Key Points: 
  • After four years of treatment with Evrysdi, many of the babies, now young children, continued to improve their ability to sit, stand and walk without support.
  • All the Evrysdi-treated children who were alive at the time of the primary analysis were still alive at month 48.
  • Additionally, the majority of infants maintained their ability to feed by mouth and swallow up to month 48.
  • Genentech leads the clinical development of Evrysdi as part of a collaboration with the SMA Foundation and PTC Therapeutics.

Roche receives FDA clearance for additional Alzheimer's disease Cerebrospinal Fluid (CSF) assays, supporting timely diagnosis and treatment decision-making

Retrieved on: 
Tuesday, June 27, 2023
CE, CT, Radiation exposure, Food and Drug Administration, Pathology, Neuroimaging, PET, Brain, Biomarker, ROG, DMTS, RO, MRI, Alzheimer's Association, Amyloid, Patient, Tau, Physician, CSF, Diagnosis, AD, FDA, Food, Caregiver, Disease, Medical imaging, Residential care, Alzheimer's disease

INDIANAPOLIS, June 27, 2023 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its Elecsys® beta-Amyloid (1-42) CSF II (Abeta42) and Elecsys® Total-Tau CSF assays (tTau) have received U.S. Food and Drug Administration (FDA) 510(k) clearance.

Key Points: 
  • INDIANAPOLIS, June 27, 2023 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its Elecsys® beta-Amyloid (1-42) CSF II (Abeta42) and Elecsys® Total-Tau CSF assays (tTau) have received U.S. Food and Drug Administration (FDA) 510(k) clearance.
  • "An early and accurate diagnosis can help patients, caregivers and physicians determine a path forward, and the Elecsys CSF assays support diagnosis at early disease stages, when treatment is most effective."
  • In addition, evaluating both amyloid and tau Alzheimer's biomarkers using PET requires multiple appointments and procedures, and increases radiation exposure.
  • Roche's Elecsys AD CSF assays are already registered in 46 countries worldwide, including those accepting the CE mark.